## Susanna Asseyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/616941/publications.pdf

Version: 2024-02-01

566801 552369 32 794 15 26 citations h-index g-index papers 33 33 33 951 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2022, 28, 757-767.	1.4	3
2	Central stress processing, T-cell responsivity to stress hormones and disease severity in multiple sclerosis. Brain Communications, 2022, 4, fcac086.	1.5	7
3	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1859-1870.	1.4	14
4	Prefrontal-amygdala emotion regulation and depression in multiple sclerosis. Brain Communications, 2022, 4, .	1.5	5
5	Anti-MOG antibody–associated disorders: differences in clinical profiles and prognosis in Japan and Germany. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 377-383.	0.9	18
6	Pain, depression, and quality of life in adults with MOGâ€antibody–associated disease. European Journal of Neurology, 2021, 28, 1645-1658.	1.7	11
7	Practical recognition tools of immunoglobulinÂG serum antibodies against the myelin oligodendrocyte glycoproteinâ€positive optic neuritis and its clinical implications. Clinical and Experimental Neuroimmunology, 2021, 12, 42-53.	0.5	4
8	Foveal changes in aquaporinâ€4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. European Journal of Neurology, 2021, 28, 2280-2293.	1.7	14
9	Anti-aquaporin 4 lgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2021, 12, 635419.	1.1	11
10	Longitudinal analysis of $T1w/T2w$ ratio in patients with multiple sclerosis from first clinical presentation. Multiple Sclerosis Journal, 2021, 27, 2180-2190.	1.4	12
11	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	41
12	AQP4-lgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110068.	0.5	6
13	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2021, 18, 105.	3.1	44
14	Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	29
15	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. Neurolmage: Clinical, 2021, 30, 102608.	1.4	9
16	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. Neurobiology of Stress, 2020, 13, 100244.	1.9	10
17	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 46, 102579.	0.9	14
18	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. Frontiers in Neurology, 2020, 11, 499910.	1.1	14

#	Article	IF	CITATIONS
19	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1:ÂResults from 163 lumbar punctures in 100 adult patients. Journal of Neuroinflammation, 2020, 17, 261.	3.1	84
20	Sex differences in brain atrophy in multiple sclerosis. Biology of Sex Differences, 2020, 11, 49.	1.8	51
21	Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Frontiers in Neurology, 2020, 11, 778.	1.1	37
22	Impact of treatment on cellular immunophenotype in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	17
23	Prodromal headache in MOG-antibody positive optic neuritis. Multiple Sclerosis and Related Disorders, 2020, 40, 101965.	0.9	41
24	Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. European Radiology, 2020, 30, 5048-5058.	2.3	9
25	Evaluation of the â€~ring sign' and the â€~core sign' as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732091548.	0.5	25
26	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. Pain, 2020, 161, 787-796.	2.0	29
27	Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. Brain Communications, 2019, 1, fcz026.	1.5	15
28	Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. NeuroImage: Clinical, 2019, 24, 102003.	1.4	93
29	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1156-1164.	0.9	20
30	Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 334.	1.1	31
31	Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline. Frontiers in Neurology, 2019, 10, 1117.	1.1	36
32	Pain in AQP4-lgG-positive and MOG-lgG-positive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731879668.	0.5	40